Entry into a Material Definitive Agreement

Business Context and Reporting Period

Company: Sharps Technology, Inc. (Note: Request metadata listed "Skyai, Inc.", but the filing identifies the registrant as Sharps Technology, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: July 24, 2024
Reporting Period: Event-based report regarding a material definitive agreement entered into on July 24, 2024.

Key Financial Metrics

This filing does not contain audited financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics for a specific fiscal period. The only financial data provided relates to the projected value of a new contract:

  • Expected Revenue: In excess of $50 million from the new Supply Agreement.
  • Contract Volume: 520 million units of 10ml PP Sologard syringes.
  • Unit Price: Confidential and redacted from the filing.

Material Changes

The primary material change is the entry into a five-year Supply Agreement with Stericare Solutions, LLC. Key terms include:

  • Product: Customized 10mL SoloGard disposable syringes.
  • Capacity Impact: The agreement sells out the available manufacturing capacity for this product line in the Company's EU facility.
  • Delivery Schedule:
    • Year 1: 40 million units.
    • Subsequent Years: 120 million units annually for the remaining life of the agreement.
  • Term: Initial five-year term commencing upon initial delivery (targeted for November 1, 2024), with automatic one-year renewals unless terminated.

Guidance, Outlook, and Risks

Management Commentary: The Company announced the agreement via press release on July 25, 2024, highlighting the full utilization of EU manufacturing capacity for the 10mL SoloGard syringe.

Termination and Risk Factors:

  • Breach: Either party may terminate if the other breaches a material term and fails to cure within 30 days.
  • Insolvency: Termination is permitted if a party becomes insolvent or files for bankruptcy (not dismissed within 120 days).
  • Acquisition: Either party may terminate with six months' written notice if the other party is acquired by a competitor.

Investor Verification Checklist

  • Verify the specific unit price and total contract value, as the filing states the price is confidential.
  • Confirm the timeline for the "Initial Delivery" targeted for November 1, 2024, to assess revenue recognition timing.
  • Review the full text of the Supply Agreement (Exhibit 10.1) for detailed performance obligations and penalty clauses not summarized in the 8-K.
  • Assess the Company's ability to meet the 120 million unit annual production requirement post-Year 1 given the "sold out" capacity status.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.